Abstract Deciphering the remote conditioning molecular mechanism may provide targets to develop therapeutics that can broaden the clinical application. To further investigate this, we tested whether two protein kinase C (PKC) isozymes, the ubiquitously expressed epsilon PKC (ePKC) and the neuronal-specific gamma PKC (cPKC), mediate nociceptive-induced remote myocardial conditioning. Male Sprague-Dawley rats were used for both in vivo and ex vivo myocardial ischemia-reperfusion protocols. For the in vivo studies, using a surgical abdominal incision for comparison, applying only to the abdomen either bradykinin or the ePKC activator (weR-ACK) reduced myocardial infarct size (45 ± 1, 44 ± 2 %, respectively, vs. incision: 43 ± 2 %, and control: 63 ± 2 %, P \ 0.001). Western blot showed only ePKC, and not cPKC, is highly expressed in the myocardium. However, applying a selective cPKC inhibitor (cV 5-3 ) to the abdominal skin blocked remote protection by any of these strategies. Using an ex vivo isolated heart model without an intact nervous system, only selective ePKC activation, unlike a selective classical PKC isozyme activator (activating a, b, b II , and c), reduced myocardial injury. Importantly, the classical PKC isozyme activator given to the abdomen in vivo (with an intact nervous system including cPKC) during myocardial ischemia reduced infarct size as effectively as an abdominal incision or weRACK (45 ± 1 vs. 45 ± 2 and 47 ± 1 %, respectively). The classical PKC activator-induced protection was also blocked by spinal cord surgical transection. These findings identified potential remote conditioning mimetics, with these strategies effective even during myocardial ischemia. A novel mechanism of nociceptive-induced remote conditioning, involving cPKC, was also identified.
Introduction
Remote conditioning either via a blood pressure cuff, by surgical abdominal incision or by femoral nerve stimulation, robustly decreases myocardial injury in rodents and canines [16, 17, 25, 28, 38] . Remote conditioning is a highly translatable technique for use in humans with planned ischemia-reperfusion events, such as coronary artery bypass grafting (CABG), and early clinical trials are encouraging [21, 46] .
There is little known whether pharmacological agents given remotely can induce cardioprotection. Presently, few pharmacological mimetics of remote conditioning exist [17, 25] . Identifying additional pharmacological mimetics to induce remote conditioning may provide a wider utility for use, including during percutaneous coronary intervention, myocardial infarction, or out of hospital arrest.
Further, the efficacy of remote conditioning during or after myocardial ischemia is largely unknown, and if effective even during ischemia, could provide an extended therapeutic window to administer remote conditioning agents.
Here, we set out to identify further the molecular mechanism leading to remote conditioning to provide therapeutic alternatives. The trigger for remote conditioning is largely unknown. However, initial studies suggest both neuronal and humoral signaling components are involved [25, 28, 38] . We focused on the neuronal-mediated component of remote conditioning and surmised perhaps the protective signal occurs via ubiquitously and neuronal-specific proteins modulating nociception.
Therefore, we investigated whether components of nociceptive signaling, including bradykinin and two protein kinase C (PKC) isozymes, are pivotal in mediating nociception-induced myocardial infarct size reduction. We focused on the ubiquitously expressed epsilon PKC (ePKC) and a PKC isozyme that is only highly expressed in neuronal cells, gamma PKC (cPKC) [4, 31, 45] . We describe here potential pharmacological mimetics, their timing to induce myocardial remote conditioning, and how this pathway is mediated via the neuronal-specific PKC isozyme, cPKC.
Methods
All animal studies conformed to the National Institute of Health Guide for the Care and Use of Laboratory Animals. The procedures and protocols used in this study were approved by the Animal Care and Use Committee at both the Medical College of Wisconsin and Stanford University. Eight to 10-week-old male Sprague-Dawley rats (Harlan Laboratories) were used for the studies outlined.
Pharmacological agents and peptide synthesis
All agents were dissolved in water. Peptides were designed based upon uniquely evolutionary conserved sequences for specific PKC isozymes or a specific isozyme class (such as classical or novel), as previously described [2, 44] . All peptides used in this manuscript were previously validated and published, including the ePKC activator (weRACK) [11, 22, 23, 42] , the ePKC inhibitor (eV 1-2 ) [14, 30] , the classical PKC activator (wbRACK) [7, 39, 40] , which selectively targets only the classical PKC isozymes (a, b I ,b II , and c), including cPKC, and the cPKC inhibitor (cV ) [26, 45] .
Activator peptides stabilize the PKC transition state via intra-molecular interactions (Fig. 1a) . The peptide sequence allows for release of a PKC isozyme allowing for cellular translocation, or as termed in this manuscript, activation. Additional peptide sequences unique to specific ePKC and cPKC isozymes were previously designed, which in turn limit isozyme binding to PKC protein partners. This is termed in this manuscript as inhibition and occurs by blocking anchoring of PKC to a protein by the peptide blocking the interaction site (Fig. 1b) . To allow for intracellular delivery, the peptide sequences were conjugated to a partial TAT sequence that penetrates cellular membranes (Fig. 1c, d) .
Agents administered included bradykinin (60 ng/kg, Tocris), TAT [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] carrier peptide (1 mg/kg) and TAT 47-57 -conjugated ePKC-and cPKC activator or inhibitor-specific peptides (1 mg/kg). Drug doses were determined based upon previous studies [17, 37] .
In vivo myocardial infarction model
The model performed was summarized in the supplemental material and previously described in a number of publications (Supplemental Methods) [15, 17] . The experimental protocol is an in vivo myocardial infarction model consisting of 30 min ischemia and 2 h of reperfusion followed by infarct size assessment. Hemodynamics, including heart rate, blood pressure and rate pressure product, arterial blood gasses, and body temperature were measured throughout the experiment. The performer of the experimental protocol, AKH, was blinded to the drugs given with each drug identity described as a random number. AKH could not be blinded to the surgical incision.
Briefly, rats were divided into groups to first test the ability for pharmacological agents to cause remote conditioning when compared to a surgical incision. Drugs were given in equal volume per weight (0.25-0.3 ml) over a surface area approximately 4 cm by 1-2 mm using a 25 gauge needle to the abdominal dermal layer. A second group of rats were used to test the involvement of ePKC and cPKC in triggering remote conditioning by surgical incision or mimetics. A surgical transection of the spinal cord at T10 was further used to test whether the effects seen by the mimetic occurs through neuronal signaling via the spinal cord. An additional series of rats were used to test whether the mimetics are effective even when given during ischemia.
Isolated heart myocardial ischemia-reperfusion Model
The protocol used has been extensively previously described [3, 23] . The performer of the experiments (TJU) was blinded to the drugs administered. Briefly, rats were anesthetized with beuthanasia and heparin given intraperitoneal to the abdomen. After adequate anesthesia was maintained, hearts were quickly excised and the aorta was secured to the aortic cannula of a Langendorff apparatus.
Hearts were perfused with Krebs buffer (120 mM NaCl, 5.8 mM KCl, 1.0 mM CaCl, 1.2 mM MgSO 4 , 25 mM NaHCO 3 , 1.2 mM NaH 2 PO 4 , 10 mM Dextrose). Left ventricular pressure balloons were made from plastic wrap as described (Cast Away Cling Wrap, gift from Dr. Jason Peart) [35] . The balloons were connected to a pressure transducer (MLT-0699, ADI Instruments) to measure left ventricular hemodynamics including, end diastolic pressure, left ventricular developed pressure, heart rate, time to contracture, ?dP/dt, and -dP/dt.
Biochemical analysis

Western blot
To determine the protein expression for cPKC and ePKC, western blotting was performed on left ventricular myocardium and spinal cord tissue homogenate. Brain homogenate was used as a positive control, in addition to recombinant protein to quantify PKC isozyme amounts in tissues. Recombinant protein was used instead of a loading control since housekeeping genes, such as GAPDH, substantially differ between tissues [12] . Tissue was excised, finely minced with scissors and homogenized with mannitol-sucrose lysis buffer (210 mM mannitol, 70 mM sucrose, 5 mM MOPS, 1 mM EDTA with pH 7.4), protease/phosphatase inhibitors and 1 % Triton-X (Sigma, St. Louis, MO). Homogenates were centrifuged at 800 g to remove cellular debris and the supernatant kept as the total fraction. Protein content was determined by Bradford assay, prepared in sample buffer at a concentration of 1 lg/ll, boiled and 30 lg of each homogenate was run on 10 % SDS page gels. Membrane proteins were transferred to PVDF membrane and probed overnight for specific antibodies to ePKC and cPKC isozymes (1:500 dilution in 5 % milk, Santa Cruz). The next day, membranes were washed and incubated in secondary anti-rabbit antibody for 90 min (1:3,000 dilution in 5 % milk, ThermoScientific). Membranes were reacted with ECL. Fig. 1 Cartoon and schematic describing PKC activator and inhibitor peptides. a PKC activator (:PKC) cartoon. PKC is present in a state allowing for intra-molecular interactions, limiting translocation and PKC-protein interaction. An activator peptide, constructed by a short peptide sequence homologous to the intra-molecular interaction site, disrupts the intra-molecular interactions, allowing a PKC isozyme to interact with a protein partner, traditionally described as a receptor for activated C kinase (RACK). b PKC inhibitor (;PKC) cartoon. Short peptide sequences unique to a PKC isozyme or PKC class limit the inter-molecular interactions between a PKC isozyme and protein partner. Inhibition is based upon limiting the ability for the PKC isozyme to interact with a RACK. c, d Amino acid location and sequences used for the peptide design of activators and inhibitors for both ePKC and cPKC. Sequences were conjugated to a partial TAT sequence consisting of amino acids 47-57 for intracellular entry [44] Statistical analysis All values were expressed as the mean ± SEM. A one-way ANOVA comparing each group to the vehicle treated group was performed to determine statistical significance for in vivo and isolated heart infarct size. A two-way ANOVA was performed to assess all hemodynamic measurements (Prism Software, La Jolla, CA).
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Results
For in vivo remote conditioning infarct size studies, 118 rats were used in 114 successful experiments. Four rats were excluded secondary to intractable ventricular fibrillation during myocardial occlusion or reperfusion (2 from eV 1-2 ? incision group, 1 from incision during ischemia group, 1 from TAT 47-57 group). No significant differences were noted in heart rate, mean arterial pressure, and rate pressure product compared to control (Supplemental Table 1 ). No significant hemodynamic differences were noted immediately after surgical incision or drug administration. No statistical differences in myocardial area at risk compared to left ventricle were noted when compared to the untreated control group (Supplemental Figure 1 and 2).
As previously reported [17] , we found that an abdominal surgical incision prior to ischemia reduced myocardial infarct size by 30 %. Either bradykinin or the ePKC activator, weRACK, given to the same abdominal area, produced a comparable myocardial infarct size reduction (Fig. 2b) . Administration of the ePKC selective inhibitor, eV 1-2 , to the abdomen prior to abdominal incision or bradykinin, blocked cardiac protection from either of these two treatments (Fig. 3b) .
We next confirmed the tissue distribution of the PKC isozymes, ePKC and cPKC, and tested whether the cPKC isozyme triggers remote nociceptive conditioning by bradykinin or surgical incision. Western blot of normoxia tissues revealed ePKC is present ubiquitously for all tissue homogenates tested. Unlike ePKC, cPKC was not expressed in left ventricular myocardial tissue homogenate (Fig. 4a) . Selective inhibition of cPKC given to the abdomen blocked cardiac protection afforded by ePKC activation, in addition to either bradykinin or surgical incision (Fig. 4c) .
To determine whether cPKC activation requires an intact nervous system, we further continued our studies using an isolated heart protocol (Fig. 5a) . For isolated heart studies, 31 rats were used for 25 successful experiments. Six rats were excluded secondary to one rat heart taking greater than 3 min to be hung on the aortic cannula, two rats with LVEDP greater than 10 mmHg at the start of baseline, two rats for failure to establish a LVDP greater than 70 mmHg, and one rat for intractable ventricular fibrillation upon reperfusion in the control group. Myocardial infarct size was similar when comparing TAT and the classical PKC activator, wbRACK, which selectively targets all classical PKC isozymes (a, b, b II , c), including cPKC, compared to control [39] . Infarct size was significantly reduced when the ePKC activator was given compared to control (Fig. 5b, c) . Neither agent significantly affected the time to contracture (Fig. 5d) . The infarct size findings were consistent with ?dP/dt, -dP/dt and the percentage recovery of LVDP at reperfusion when compared to baseline LVDP values (Fig. 5e-g ). No baseline differences in heart rate, LVDP, or EDP were noted (Supplemental Table 2 ).
We next found although the cPKC activator was ineffective ex vivo, the cPKC activator delivered to the abdomen in vivo during ischemia reduced myocardial infarct size (Fig. 6b) . To confirm cPKC-mediated activation is mediated by a neuronal signal, we severed the spinal cord at T10, above the site of where the cPKC activator was administered. Although displaying no noticeable hemodynamic effects after the cord was severed at T10 (Supplemental Table 3 ), the cPKC activator when given to the abdomen failed to reduce myocardial infarct size (Fig. 6b) . Further, the cPKC activator-induced myocardial salvage mimicked the protection of an abdominal incision or the ePKC activator when given during ischemia (Fig. 7b) . In contrast, the protection induced by an abdominal surgical incision did not reduce infarct size when performed immediately after reperfusion (Fig. 7b) Neuronal-specific cPKC inhibition blocks nociceptiveinduced remote conditioning a western blot of rat heart left ventricle and spinal cord for ePKC and cPKC. Both brain tissue and recombinant protein for ePKC and cPKC were used as a positive control. Although ePKC is ubiquitously expressed, cPKC is only expressed in the nervous system. b Experimental protocol with either TAT or the cPKC inhibitor (;cPKC) given 25 min before ischemia. Some groups received either bradykinin, the ePKC activator (:ePKC) or an abdominal incision, 15 min before ischemia. c The cPKC inhibitor (;cPKC) blocks protection of bradykinin, :ePKC, or abdominal incision. ? P \ 0.001 versus TAT ? incision group. The individual infarct sizes for each animal are plotted in addition to the mean ± SEM numerical values listed below each individual group. A dashed line represents the average infarct size seen by the TAT ? incision group (44 ± 1 %) presented in Fig. 3b for comparison and cPKC activators had no effects on hemodynamics when compared to the abdominal incision groups (Supplemental Table 3 ).
Discussion
Although remote preconditioning of the myocardium is well described, besides capsaicin, pharmacological strategies to mimic the effect have not been identified [25, 28] . Here we describe cardioprotective mimetic agents given remotely that target a cPKC-dependent neuronal pathway and reduce myocardial injury even when given during ischemia. The mimetics used had no negative hemodynamic effects, avoiding the potential for further ischemic injury by increasing myocardial demand when triggering a nociceptive-inducing pathway. We also demonstrate a specific role for cPKC, which is expressed only in neurons, in mediating remote nociceptive-induced cardioprotection.
The contribution of cPKC in tissue protection is not unprecedented since cPKC is important to reduce injury from ischemia in the brain [1, 19] and oxidative stress in the lens [29] . How cPKC mediates the signal caused by the abdominal intervention to the heart is likely through the highly innervated abdominal skin, since cPKC was present in homogenized mouse skin transmitting a signal to the spinal cord [27] . This is supported by findings that a neuronal-specific fluorescent dye, dil, locally injected to the abdominal skin at the same site of our abdominal incision travels from the abdominal neurons, to the spinal cord, and up to nerve endings innervating the heart at T1-T4 [25] . Moreover, the pathway inducing cardioprotection does not require input from the brain since transection above C7 does not alter the incision-induced cardioprotective effect [25] .
In the spinal cord, cPKC is selectively localized to the posterior dorsal horn mainly in Rexed lamina II (substantia gelatinosa) [34] , with perhaps a portion of cPKC localized in lamina I and lamina III [36] . Interestingly, lamina II is d Time to contracture for each heart during ischemia. e, f 1dP/dt and -dP/dt assessed at 90 min of reperfusion. g Percentage of LVDP recovery from baseline for each group assessed at 5, 10, 15, 30, 60, and 90 min after reperfusion. *P \ 0.05 versus vehicle, TAT or :cPKC, n = 6-7/group, data presented as mean ± SEM highly populated with opioid receptors [49] , and where unmyelinated C fibers and a portion of the myelinated nerve fibers terminate. Positive stained cPKC neurons in lamina II were those of the myelinated nerve fibers, rather than unmyelinated fibers [34] . In a cPKC knockout mouse, deletion of cPKC alters neurotransmitter release of substance P, neurokinin-1 and neuropeptide Y during sciatic nerve injury [31] . Thus, cPKC, unlike other PKC isozymes, is selectively expressed only in the brain, peripheral nerves, and select regions of the spinal cord that in turn regulate neurotransmitter release.
Although we did not provide biochemical evidence displaying cPKC translocation in the spinal cord, two independent pain studies using a paw surgical incision showed an incision-induced translocation of cPKC from the cytosolic to particulate fraction in the spinal cord by Western blot that persisted for hours [9, 48] . Specifically, of all classical PKC isozymes, only cPKC translocation after incision was noted in the spinal cord, with a, b I , and b II isozymes unchanged [48] . After nerve injury, cPKC knockout mice display less neuropathic pain behavior and further, cV 5-3 reduces pain response in strychnine injected rats [31, 33] . In addition, formalin-induced translocation of cPKC is blocked by the administration of the ePKC inhibitor, eV 1-2 [45] . These data, in combination with our present findings, support the role for cPKC in mediating the cardioprotective signal of an abdominal incision and the incision mimetics via nociceptive pathways.
As a classical PKC isozyme, translocation of cPKC from the cytosol to membrane is dependent upon calcium, unlike the ePKC and dPKC isozymes belonging to the novel PKC isozyme class. A number of protein partners for cPKC were identified through proteomic analysis [51] and recent evidence suggests a cPKC-synapsin pathway may be important for hypoxia-induced neuroprotection [51] . In turn, cPKC subsequently regulates receptors including opioids, NMDA, AMPA, GLUR1 and TRPV1 [24, 32, 48] , which all may be potential candidates to further initiate the cardioprotective signal. In addition, whether the humoral component of remote cardioprotection, previously shown by others [28, 38] , is connected to the nociceptive-mediated pathway, will require further examination. Remote cardioprotection is dependent on the sympathetic nervous system, without parasympathetic nerve involvement [25] . The classical PKC peptide, activating a, b I , b II , and c PKC, without an intact nervous system in isolated hearts, was ineffective at reducing myocardial infarct size, even though both a and b PKC are present in the adult rat heart [41] . Additionally, when directly applied to myocytes, the classical PKC activator did not reduce ischemic injury [7] , indicating cPKC reduces myocardial infarct size only remotely. Findings in homogenized human hearts suggest that cPKC is expressed in the myocardium only at a very low abundance (\1 ng/lg tissue) [18] . Since cPKC is present in only heart homogenates and not expressed in the rat ventricle-derived H9C2 cell line, nerve endings expressing cPKC are likely present in the homogenized tissue [18, 50] .
Moreover, since ePKC is ubiquitously expressed, ePKC provides a dual role as a specific trigger, initiating the cardioprotective signal in remote tissue and also acting as an end effector at the myocardium after the signal is transmitted through the neuronal system [23, 25] . This is supported by our findings that 1) abdominal administration of the ePKC activator is blocked by cPKC inhibition, and 2) when the ePKC activator is given directly to the heart in an isolated heart model, the ePKC activator is also cardioprotective. Where PKC signaling contributes to other components as triggers of this pathway, including nitric oxide [38] and end effectors such as STAT5 [20] , will need further elucidation. The contribution of ePKC in remote cardioprotection is also supported since aldehyde dehydrogenase 2 (ALDH2), downstream of ePKC, is required for remote cardioprotection in humans [6, 8] .
The ability for remote conditioning to protect the myocardium during ischemia by a surgical incision, ePKC, or cPKC activation also suggests that an extended window exists into the ischemic period that produces remote conditioning. This finding also supports that a surgical incision is just as protective during as compared to before myocardial ischemia [25] . We extend these findings to show a surgical incision is ineffective after reperfusion. Our study should be interpreted with considerations of the following limitations. The reperfusion period selected for these studies was short, however, our studies here were aimed to identify additional mimetics and the molecular mechanism of remote conditioning. We were able to compare the effects of these mimetics with prior studies, showing the degree of myocardial infarct size reduction is comparable to bradykinin, opioids, glycogen synthase kinase 3b inhibitors, and K ATP channel openers given intravenously [15, 17] . To determine the therapeutic potential for these newly discovered remote conditioning mimetics, investigating longer reperfusion periods and cardiac functional status weeks after a myocardial infarction will be a focus of future studies.
The cPKC isozyme, with the slight ataxia reported for the cPKC knockout mouse [5] , parallels the finding human ataxia occurs by point mutations in the cPKC C1 domain region [10] . Even though in general PKC isozyme differences may occur based on the species used [47] , cPKC isozyme function appears similar across mammalian species. Additionally, an abdominal incision is effective in reducing myocardial damage in a canine large animal model [16] . However, since the signaling cascades of cardioprotection differ between species and in particular larger animals [43] , more validation of this molecular pathway in large animals will be needed. Further, since the classical PKC activator in this study is not specific for the C2 domain of cPKC, and sustained activation of aPKC and bPKC are linked to the pathophysiology of heart failure [13] , a peptide that selectively activates only cPKC, instead of all classical isozymes will also be an area of further investigation.
We also cannot completely exclude the agents administered subdermal reach the circulation. However, our findings support this does not occur since 1) surgical transection of the spinal cord blocks the protective effect of the classical PKC activator and 2) the ePKC activator, if reaching the circulation, should reduce infarct size in the presence of the cPKC inhibitor, cV 5-3 .
Here we identified cPKC as a neuronal trigger for remote cardioprotection. A summary for the proposed signaling process leading to remote cardioprotection is shown (Fig. 8 ). The cardioprotective mimetics described here are effective when applied remotely. Importantly, this treatment is beneficial even during ischemia. Although requiring further study, these findings may have broad applications for organ preservation from ischemic damage during transplantation, percutaneous coronary interventions, myocardial infarction, and out of hospital arrest.
